Cargando…

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

BACKGROUND: Streptozocin (STZ) based chemotherapy is recommended for patients with metastatic pancreatic neuroendocrine tumors (pNET). Temozolomide as mono- or combination therapy has been suggested to be a promising alternative. However, the treatment is costly and not approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Daniela, Krug, Sebastian, Majumder, Moushumee, Rinke, Anja, Gress, Thomas Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989525/ https://www.ncbi.nlm.nih.gov/pubmed/27538897 http://dx.doi.org/10.1186/s12885-016-2642-1

Ejemplares similares

Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome
por: Krug, Sebastian, et al.
Publicado: (2019)

Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms – Predictive and Prognostic Markers for Treatment Stratification
por: Krug, Sebastian, et al.
Publicado: (2015)

Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature
por: Krug, Sebastian, et al.
Publicado: (2016)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
por: Krug, Sebastian, et al.
Publicado: (2021)

Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms
por: Koenig, Alexander, et al.
Publicado: (2017)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Paraneoplastic brainstem encephalitis in a patient with exceptionally long course of a metastasized neuroendocrine rectum neoplasm
por: Boch, Michael, et al.
Publicado: (2014)

CUX1—Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors
por: Krug, Sebastian, et al.
Publicado: (2020)

Multicenter Analysis of Presacral Neuroendocrine Neoplasms—Clinicopathological Characterization and Treatment Outcomes of a Rare Disease
por: Matrood, Sami, et al.
Publicado: (2021)

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

The Patient’s Point of View: COVID-19 and Neuroendocrine Tumor Disease
por: Krug, Sebastian, et al.
Publicado: (2022)

Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice
por: Luecke, Simone, et al.
Publicado: (2022)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
por: Birkeland, Einar, et al.
Publicado: (2013)

Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality
por: Krug, Sebastian, et al.
Publicado: (2021)

DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.
por: Marelli, O., et al.
Publicado: (1988)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
por: Lee, S. M., et al.
Publicado: (1994)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Updates on Diagnostic and Therapeutic Management of Gastrointestinal and Pancreatic NET
por: Krug, Sebastian, et al.
Publicado: (2022)

Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma
por: Apostolidis, Leonidas, et al.
Publicado: (2016)

Primary Well-Differentiated Neuroendocrine Tumor of the Kidney
por: Prasad, Vishnu, et al.
Publicado: (2023)

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017)

Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
por: Lee, S. M., et al.
Publicado: (1993)

DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo
por: Ding, Baoyue, et al.
Publicado: (2016)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

Vessel-Sparing Lymphadenectomy Should Be Performed in Small Intestine Neuroendocrine Neoplasms
por: Bartsch, Detlef K., et al.
Publicado: (2022)

Two well-differentiated pancreatic neuroendocrine tumor mouse models
por: Wong, Chung, et al.
Publicado: (2019)

Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
por: Das, Satya, et al.
Publicado: (2021)

Are Small Rectal Neuroendocrine Tumors Safe?
por: Choi, Jae Ho, et al.
Publicado: (2015)

Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
por: Volante, Marco, et al.
Publicado: (2021)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients
por: Palermo, Belinda, et al.
Publicado: (2018)

Transanal Endoscopic Microsurgery for the Treatment of Well-Differentiated Rectal Neuroendocrine Tumors
por: Kim, Hyoung Ran, et al.
Publicado: (2012)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

Clinical and Pathological Features of Primary Renal Well-Differentiated Neuroendocrine Tumor
por: Jiang, Hua, et al.
Publicado: (2022)

Gallbladder primary well-differentiated neuroendocrine tumor: A misdiagnosed case
por: Dammak, Nouha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_357h7lo4jvnqjm1b5mhkjib5sj